13,155 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Cibc World Markets Corp

Cibc World Markets Corp acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,155 shares of the company's stock, valued at approximately $361,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BBIO. Ironwood Investment Management LLC increased its holdings in shares of BridgeBio Pharma by 0.5% during the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company's stock valued at $1,733,000 after acquiring an additional 338 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after purchasing an additional 472 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock worth $117,000 after buying an additional 1,645 shares in the last quarter. E Fund Management Co. Ltd. grew its holdings in shares of BridgeBio Pharma by 13.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 17,785 shares of the company's stock valued at $488,000 after buying an additional 2,151 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of BridgeBio Pharma by 1.1% during the third quarter. Swiss National Bank now owns 219,300 shares of the company's stock valued at $5,583,000 after buying an additional 2,400 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

BBIO has been the topic of several analyst reports. Scotiabank upped their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Friday, February 21st. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Monday, December 23rd. HC Wainwright restated a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Finally, Citigroup lifted their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $52.90.

Insider Buying and Selling at BridgeBio Pharma

In related news, CFO Brian C. Stephenson sold 68,000 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $2,467,720.00. Following the completion of the transaction, the chief financial officer now owns 93,758 shares of the company's stock, valued at approximately $3,402,477.82. This represents a 42.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 326,932 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28. Following the sale, the chief executive officer now directly owns 5,371,515 shares in the company, valued at approximately $194,932,279.35. This represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,654,739 shares of company stock valued at $325,937,151 over the last 90 days. 24.66% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Trading Down 3.5 %

BBIO stock traded down $1.29 during midday trading on Friday, reaching $35.11. 1,191,490 shares of the company's stock traded hands, compared to its average volume of 2,194,154. The stock's 50-day moving average is $34.24 and its 200 day moving average is $29.26. The stock has a market cap of $6.68 billion, a P/E ratio of -12.32 and a beta of 1.07. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. As a group, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.